Outcomes In Heartmate 3 (HM3) Vs Heartware (HVAD) Patients: A Single Center Experience
HFSA ePoster Library. Goyal A. 09/10/21; 343422; 193
Dr. Amandeep Goyal
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Background:The management of concurrent cardiac amyloidosis (CA) and ischemic cardiomyopathy (ICM) is not well established due to the rarity of this phenomenon. We present a case of mixed cardiomyopathy with challenging clinical decision-making.
Case: A 76-year-old African American woman with hypertension, diabetes, and longstanding carpal tunnel syndrome presented with progressive dyspnea and was found to have decompensated heart failure attributable to a new cardiomyopathy. Initial workup revealed left ventricular ejection fraction (LVEF) of 20% and severe triple vessel coronary artery disease. Echocardiogram also demonstrated an apical-sparing strain pattern (Figure 1A) prompted concern for coexisting CA given her demographic and carpal tunnel history. A cardiac magnetic resonance (CMR) raised further concern for CA given restrictive cardiomyopathy, pericardial effusion, and characteristic late gadolinium enhancement (Figure 1B and 1C). Ultimately, transthyretin CA (ATTR) was confirmed with a positive technetium-99m-Pyrophosphate Scintigraphy (PYP) scan (Figure 1D) paired with normal serum immunofixation electrophoresis. She was evaluated by cardiothoracic surgery but deemed a prohibitively high-risk candidate for CABG due to her advanced age, ATTR diagnosis, and significant systolic dysfunction. Instead, she was diuresed and started on guideline-directed medical therapy, which she tolerated unusually well despite her diagnosis of ATTR. Using Impella CP for temporary mechanical circulatory support, she underwent high-risk percutaneous coronary intervention to the distal left main artery extending into the proximal left circumflex. She was discharged on dual antiplatelet therapy. During outpatient follow-up in the Multidisciplinary CA Clinic, genetic testing revealed a pathogenic V122I mutation indicative of hereditary ATTR. She was started on tafamidis after nerve conduction studies did not demonstrate neuropathy. The combination of guideline-directed medical therapy, successful percutaneous revascularization, and ATTR-directed treatment resulted in remarkable improvement (NYHA Class II, LVEF 50% from NYHA IV, LVEF 20%).
Conclusion:Further investigation is needed to define optimal treatment strategies in patients with coexisting ischemic and amyloid cardiomyopathy. Until then, a multidisciplinary approach must be utilized to individualize the care of such patients.
Case: A 76-year-old African American woman with hypertension, diabetes, and longstanding carpal tunnel syndrome presented with progressive dyspnea and was found to have decompensated heart failure attributable to a new cardiomyopathy. Initial workup revealed left ventricular ejection fraction (LVEF) of 20% and severe triple vessel coronary artery disease. Echocardiogram also demonstrated an apical-sparing strain pattern (Figure 1A) prompted concern for coexisting CA given her demographic and carpal tunnel history. A cardiac magnetic resonance (CMR) raised further concern for CA given restrictive cardiomyopathy, pericardial effusion, and characteristic late gadolinium enhancement (Figure 1B and 1C). Ultimately, transthyretin CA (ATTR) was confirmed with a positive technetium-99m-Pyrophosphate Scintigraphy (PYP) scan (Figure 1D) paired with normal serum immunofixation electrophoresis. She was evaluated by cardiothoracic surgery but deemed a prohibitively high-risk candidate for CABG due to her advanced age, ATTR diagnosis, and significant systolic dysfunction. Instead, she was diuresed and started on guideline-directed medical therapy, which she tolerated unusually well despite her diagnosis of ATTR. Using Impella CP for temporary mechanical circulatory support, she underwent high-risk percutaneous coronary intervention to the distal left main artery extending into the proximal left circumflex. She was discharged on dual antiplatelet therapy. During outpatient follow-up in the Multidisciplinary CA Clinic, genetic testing revealed a pathogenic V122I mutation indicative of hereditary ATTR. She was started on tafamidis after nerve conduction studies did not demonstrate neuropathy. The combination of guideline-directed medical therapy, successful percutaneous revascularization, and ATTR-directed treatment resulted in remarkable improvement (NYHA Class II, LVEF 50% from NYHA IV, LVEF 20%).
Conclusion:Further investigation is needed to define optimal treatment strategies in patients with coexisting ischemic and amyloid cardiomyopathy. Until then, a multidisciplinary approach must be utilized to individualize the care of such patients.
Background:The management of concurrent cardiac amyloidosis (CA) and ischemic cardiomyopathy (ICM) is not well established due to the rarity of this phenomenon. We present a case of mixed cardiomyopathy with challenging clinical decision-making.
Case: A 76-year-old African American woman with hypertension, diabetes, and longstanding carpal tunnel syndrome presented with progressive dyspnea and was found to have decompensated heart failure attributable to a new cardiomyopathy. Initial workup revealed left ventricular ejection fraction (LVEF) of 20% and severe triple vessel coronary artery disease. Echocardiogram also demonstrated an apical-sparing strain pattern (Figure 1A) prompted concern for coexisting CA given her demographic and carpal tunnel history. A cardiac magnetic resonance (CMR) raised further concern for CA given restrictive cardiomyopathy, pericardial effusion, and characteristic late gadolinium enhancement (Figure 1B and 1C). Ultimately, transthyretin CA (ATTR) was confirmed with a positive technetium-99m-Pyrophosphate Scintigraphy (PYP) scan (Figure 1D) paired with normal serum immunofixation electrophoresis. She was evaluated by cardiothoracic surgery but deemed a prohibitively high-risk candidate for CABG due to her advanced age, ATTR diagnosis, and significant systolic dysfunction. Instead, she was diuresed and started on guideline-directed medical therapy, which she tolerated unusually well despite her diagnosis of ATTR. Using Impella CP for temporary mechanical circulatory support, she underwent high-risk percutaneous coronary intervention to the distal left main artery extending into the proximal left circumflex. She was discharged on dual antiplatelet therapy. During outpatient follow-up in the Multidisciplinary CA Clinic, genetic testing revealed a pathogenic V122I mutation indicative of hereditary ATTR. She was started on tafamidis after nerve conduction studies did not demonstrate neuropathy. The combination of guideline-directed medical therapy, successful percutaneous revascularization, and ATTR-directed treatment resulted in remarkable improvement (NYHA Class II, LVEF 50% from NYHA IV, LVEF 20%).
Conclusion:Further investigation is needed to define optimal treatment strategies in patients with coexisting ischemic and amyloid cardiomyopathy. Until then, a multidisciplinary approach must be utilized to individualize the care of such patients.
Case: A 76-year-old African American woman with hypertension, diabetes, and longstanding carpal tunnel syndrome presented with progressive dyspnea and was found to have decompensated heart failure attributable to a new cardiomyopathy. Initial workup revealed left ventricular ejection fraction (LVEF) of 20% and severe triple vessel coronary artery disease. Echocardiogram also demonstrated an apical-sparing strain pattern (Figure 1A) prompted concern for coexisting CA given her demographic and carpal tunnel history. A cardiac magnetic resonance (CMR) raised further concern for CA given restrictive cardiomyopathy, pericardial effusion, and characteristic late gadolinium enhancement (Figure 1B and 1C). Ultimately, transthyretin CA (ATTR) was confirmed with a positive technetium-99m-Pyrophosphate Scintigraphy (PYP) scan (Figure 1D) paired with normal serum immunofixation electrophoresis. She was evaluated by cardiothoracic surgery but deemed a prohibitively high-risk candidate for CABG due to her advanced age, ATTR diagnosis, and significant systolic dysfunction. Instead, she was diuresed and started on guideline-directed medical therapy, which she tolerated unusually well despite her diagnosis of ATTR. Using Impella CP for temporary mechanical circulatory support, she underwent high-risk percutaneous coronary intervention to the distal left main artery extending into the proximal left circumflex. She was discharged on dual antiplatelet therapy. During outpatient follow-up in the Multidisciplinary CA Clinic, genetic testing revealed a pathogenic V122I mutation indicative of hereditary ATTR. She was started on tafamidis after nerve conduction studies did not demonstrate neuropathy. The combination of guideline-directed medical therapy, successful percutaneous revascularization, and ATTR-directed treatment resulted in remarkable improvement (NYHA Class II, LVEF 50% from NYHA IV, LVEF 20%).
Conclusion:Further investigation is needed to define optimal treatment strategies in patients with coexisting ischemic and amyloid cardiomyopathy. Until then, a multidisciplinary approach must be utilized to individualize the care of such patients.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}